SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
EUDA Health Holdings Limited (EUDA) has a negative trailing P/E of -28.1, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 57.3 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -3.56%, forward earnings yield 1.74%.
Criteria proven by this page:
- VALUE (100/100, Pass) — composite valuation score exceeds the 60/100 pass threshold.
- Forward P/E 57.3 — analysts expect a return to profitability with estimated EPS of $0.12 for FY2026.
- Trailing Earnings Yield -3.56% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings. Forward yield improves to 1.74% as earnings recover.
Overall SharesGrow Score: 37/100 with 2/7 criteria passed.
SharesGrow 7-Criteria Score
✓
VALUE
100/100
Price-to-Earnings & upside
Proven by this page
✗
HEALTH
0/100
Debt-to-Equity & liquidity
→ Health
Valuation Snapshot — EUDA
Valuation Multiples
P/E (TTM)-28.1
Forward P/E57.3
PEG RatioN/A
Forward PEGN/A
P/B Ratio-3.54
P/S Ratio3.26
EV/EBITDA-10.2
Per Share Data
EPS (TTM)$-0.25
Forward EPS (Est.)$0.12
Book Value / Share$-2.01
Revenue / Share$2.21
FCF / Share$-0.90
Yields & Fair Value
Earnings Yield-3.56%
Forward Earnings Yield1.74%
Dividend Yield0.00%
Historical Valuation
| Year |
P/E (TTM) |
PEG Ratio |
P/B Ratio |
P/S Ratio |
Dividend Yield |
| 2020 |
407.9 |
0.00 |
-198.63 |
8.07 |
- |
| 2021 |
104.3 |
0.35 |
173.09 |
19.79 |
- |
| 2022 |
-0.8 |
0.00 |
-5.63 |
5.26 |
- |
| 2023 |
-3.9 |
0.05 |
-5.20 |
10.51 |
- |
| 2024 |
-9.4 |
-0.35 |
-56.83 |
36.17 |
- |
P/E Ratio & Earnings Yield
Earnings Per Share (EPS) History
| Year |
EPS (Diluted) |
Revenue |
Net Income |
Net Margin |
| 2020 |
$0.02 |
$8.88M |
$175.58K |
2% |
| 2021 |
$0.09 |
$10.54M |
$864.83K |
8.2% |
| 2022 |
$-2.07 |
$9.84M |
$-24.88M |
-252.9% |
| 2023 |
$-0.44 |
$3.71M |
$-10.04M |
-270.9% |
| 2024 |
$-0.47 |
$4.01M |
$-15.36M |
-382.9% |
Analyst Estimates
| Year |
EPS (Avg) |
EPS Range |
Revenue (Avg) |
Revenue Range |
Analysts |
| 2026 |
$0.12 |
$0.12 – $0.12 |
$43.5M |
$43.5M – $43.5M |
1 |
